Anti-p16-INK4a, cl 5F22 ZooMAb� Rb mono

Application

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected p16-INK4a in HeLa, A431, HUVEC, and NIH3T3 cells.Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected p16-INK4a in human cervical cancer tissue sections.Affinity Binding Assay: A representative lot of this antibody bound recombinant p16-INK4a protein with a KD of 4.5 x 10-7 in an affinity binding assay.Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Anti-p16-INK4a, clone 5F22, ZooMAb, Cat. No. ZRB1437, is a recombinant Rabbit monoclonal antibody that specifically targets p16-INK4a and is tested in Affinity Binding Assay, Immunocytochemistry, Immunohistochemistry (Paraffin), and Western Blotting.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.Learn more about ZooMAb here.

Immunogen

GST/His-tagged recombinant fragment corresponding to the first 54 amino acids from human Cyclin-dependent kinase inhibitor 2A (p16-INK4a).

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Physical form

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

Reconstitution

0.3 mg/mL after reconstitution at 25µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Specificity

Clone 5F22 is a ZooMAb rabbit recombinant monoclonal antibody that specifically detects Cyclin-dependent kinase inhibitor 2A (p16-INK4a). It targets an epitope within the first 54 amino acids from the N-terminal.

Storage and Stability

Recommended storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Target description

Cyclin-dependent kinase inhibitor 2A (UniProt: P42771; also known as Cyclin-dependent kinase 4 inhibitor A, CDK4I, Multiple tumor suppressor 1, MTS-1, p16-INK4a, p16-INK4, p16INK4A) is encoded by the CDKN2A (also known as CDKN2, MTS1) gene (Gene ID: 1029) in human. p16-INK4 is a widely distributed protein that acts as a negative regulator of proliferation of normal cells. It is reported to be the principal member of the IINK4 family of CDK inhibitors. It heterodimerizes with CDK4 or CDK6 and inhibits their ability to interact with cyclin D and to phosphorylate the retinoblastoma protein. It is considered a tumor suppressor protein because of physiological role and down-regulated expression in a large number of tumors. Overexpression of p16-INK4a has also been described in several tumors, including endometrial, colorectal and basal cell carcinoma. Six isoforms of p16-INK4a have been described that are produced by alternative splicing. This ZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.